Heron Therapeutics(HRTX) - 2023 Q4 - Earnings Call Presentation

2 Gross margin improvement from the 50% range historically to over 70% Completed capital raise - $30M in Equity and$50M in debt, pulled down $25M ($55M in total); Current cash and cash equivalents/investments at the end of December was over $80M 5 Announced partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF promotional efforts on January 7, 2024; January 23, 2024 label expansion 3 Vial Access Needle (VAN) and Prefilled Syringe (PFS) are all budgeted and making progress 3 months ended December ...